Effects of a Peptide Derived from the Primary Sequence of a Kallikrein Inhibitor Isolated from Bauhinia bauhinioides (pep-BbKI) in an Asthma-COPD Overlap (ACO) Model

• Published in: International journal of molecular sciences Vol. 24; no. 14; p. 11261
• Main Authors: Silva, Luana Laura Sales da, Barbosa, Jéssica Anastácia Silva, João, Juliana Morelli Lopes Gonçalves, Fukuzaki, Silvia, Camargo, Leandro do Nascimento, Dos Santos, Tabata Maruyama, Campos, Elaine Cristina de, Costa, Arthur Silva, Saraiva-Romanholo, Beatriz Mangueira, Bezerra, Suellen Karoline Moreira, Lopes, Fernanda Tenório Quirino Dos Santos, Bonturi, Camila Ramalho, Oliva, Maria Luiza Vilela, Leick, Edna Aparecida, Righetti, Renato Fraga, Tibério, Iolanda de Fátima Lopes Calvo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09.07.2023; MDPI
• Subjects: ACO; Airway management; airway remodeling; Asthma; Bauhinia; Chronic obstructive pulmonary disease; Enzymes; Inflammation; Neutrophils; Oxidative stress; Peptides; Respiratory system; serine proteinase inhibitors; Steroids; Bauhinia; inflammation; ACO; serine proteinase inhibitors; oxidative stress; airway remodeling
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms241411261

(1) There are several patients with asthma-COPD overlap (ACO). A peptide derived from the primary sequence of a kallikrein inhibitor isolated from (pep-BbKI) has potent anti-inflammatory and antioxidant effects. Purpose: To investigate the effects of pep-BbKI treatment in an ACO model and compare them with those of corticosteroids. (2) BALB/c mice were divided into groups: SAL (saline), OVA (ovalbumin), ELA (elastase), ACO (ovalbumin + elastase), ACO-pep-BbKI (treated with inhibitor), ACO-DX (dexamethasone treatment), ACO-DX-pep-BbKI (both treatments), and SAL-pep-BbKI (saline group treated with inhibitor). We evaluated: hyperresponsiveness to methacholine, bronchoalveolar lavage fluid (BALF), exhaled nitric oxide (eNO), IL-1β, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IFN-γ, TNF-α, MMP-9, MMP-12, TGF-β, collagen fibers, iNOS, eNO, linear mean intercept (Lm), and NF-κB in airways (AW) and alveolar septa (AS). (3) ACO-pep-BbKI reversed ACO alterations and was similar to SAL in all mechanical parameters, Lm, neutrophils, IL-5, IL-10, IL-17, IFN-γ, TNF-α, MMP-12 (AW), collagen fibers, iNOS (AW), and eNO ( > 0.05). ACO-DX reversed ACO alterations and was similar to SAL in all mechanical parameters, Lm, total cells and differentials, IL-1β(AS), IL-5 (AS), IL-6 (AS), IL-10 (AS), IL-13 (AS), IFN-γ, MMP-12 (AS), TGF-β (AS), collagen fibers (AW), iNOS, and eNO ( > 0.05). SAL was similar to SAL-pep-BbKI for all comparisons ( > 0.05). (4) Pep-BbKI was similar to dexamethasone in reducing the majority of alterations of this ACO model.